12 Oct Lavipharm launches a new pharmaceutical product for erectile dysfunction
Peania, 12 October 2022 – Lavipharm is releasing a new tadalafil pharmaceutical product on the Greek market indicated for the treatment of erectile dysfunction, as well as of the symptoms of benign prostatic hyperplasia in adult men. This new product further enhances Lavipharm’s long-standing, dynamic and well-established presence in this therapeutic category.
Erectile dysfunction is considered a benign disorder related to physical and psychosocial health, with a significant impact on patients’ quality of life. Data show that moderate to severe erectile dysfunction affects a significant proportion of the male population, with this proportion increasing with age. In addition, most patients with symptoms of benign prostatic hyperplasia present erectile dysfunction, although no causal relationship between the two conditions has been established. As erectile dysfunction shares common risk factors with coronary artery disease, early diagnosis and appropriate treatment can have beneficial outcomes for patients while preventing cardiovascular incidents.
“Effective treatment of erectile dysfunction is a continuing medical challenge, mainly due to the psychosocial dimension it has received from patients,” said Mr Aristides Polyvos, Head of Marketing Rx & Oncology at Lavipharm Hellas. “Talys® significantly enriches available therapeutic options for every healthcare professional, while it also expands Lavipharm’s product portfolio in this therapeutic category. With the release of Talys®, our aim is to make a significant contribution to the optimal treatment of erectile dysfunction as well as of the symptoms of benign prostatic hyperplasia, while creating a successful product in a highly competitive market.”
Lavipharm’s tadalafil pharmaceutical product is available on the Greek pharmaceutical market in three strengths to effectively target the needs of each patient.
With a history of over a century, Lavipharm has been active in the pharmaceutical industry since 1911, always aiming to help doctors and pharmacists in their practice by providing reliable therapeutic options. Its portfolio includes innovative and effective products which respond to the daily needs of patients.